制作具有稳定磁性、能够携带化疗药物的白蛋白纳米粒，并对白蛋白纳米粒的磁性、药物含量进行检测。方法：将市售用Fe3O4粉末，经化学方法处理，制成纳米大小的Fe3O4泥糊，将Fe3O4泥糊、纯盐酸阿霉素、人体血清白蛋白按一定比例混合，通过在棉仔油中超声乳化、加热变性、乙醚洗涤等工艺制作出磁性阿霉素白蛋白纳米粒，用乙醇提取法提取磁性纳米粒中的阿霉素，并用荧光光度计测定含量。将纳米粒溶于生理盐水中，在光学显微镜下观察在磁场作用下磁性纳米粒的运动情况。通过检测溶液中的游离药物，观察在不同的加热温度下，磁性纳米粒的稳定性，并用电子显微镜观察纳米粒的内部结构。结果：磁性白蛋白纳米粒阿霉素含量为57.5μg/g，阿霉素包含率为98.3%，磁性白蛋白纳米粒溶液在光学显微镜下观察，在磁场的作用下，纳米粒迅速向磁铁的方向移动并发生聚集，当磁铁与纳米粒的距离加大时，纳米粒运动速度减慢，并沿磁力线的方向形成串珠状聚集。电子显微镜下观察，Fe3O4颗粒均匀分布在白蛋白纳米粒中。结论：磁性白蛋白纳米粒具有磁性稳定、靶向性强、药物包含率高、释药速率可控制的特点，为靶向药物治疗提供了可靠的载药工具。

Objective: To compare the targeting effects of lactosaminated alginate (AlgNP)、polyethylene glycol-coated hydroxyapatite-poly-L-lysine nanoparticles (PLL-PCHNP) and relative nonlactosaminated ones loaded with exogenous gene on liver via peripheral intravenous route. Methods: Preparation of AlgNP based on control of gelification phenomenon of algiante by calcium ions and HA-PLLNP with collosol-gel method, both further modified with lactosaminated-poly-L-lysine synthesized by reductive lactosamination. We used pEGFPc1 as the reporter gene to establish receptor-mediated and positive liver targeting nanoparticles-gene model. The potential of adsorbing DNA on nanoparticles was analysed by electrophoresis and spectrophotometer. Then different complexes were transferred into the rat'S body by peripheral intravenous route and their targeting characteristics in liver were investigated by using radioisotope tracing assay. Results: PCHNP presented as needle-like particles with a diameter of 20nm by TEM and could be effectively combined with PLL．The diameter of AlgNP was 280nm．Agarose gel electrophoresis showed both nanoparticles could effectively combine with DNA and the optimal proportion of PLLPCHNP and DNA was 30:l (w/w); DNA mixed ratio of AlgPLL was 68.3%by spectrophotometer. The radioactivities in liver for the two lactosaminated nanoparticles were higher than the nonlactosaminated ones. No statistic difference between AlgNP and AlgLacNP could be found. Conclusions: Lactosaminated nanoparticles can target to liver more effectively by peripheral intravenous route than nonlactosaminated ones, which is closely concerned with the characteritics of the nanoparticle complex.